Metastatic progression of breast cancer along with decreased mitochondrial cell death priming of breast cancer cells: a case report

Abstract Metastatic breast cancer remains to be a major cause of cancer-related deaths in women. Exploring the molecular mechanisms to identify targetable alterations in progressing breast cancer and developing functional tools to predict therapy response in these patients are needed. In this report...

Full description

Saved in:
Bibliographic Details
Published in:Oxford Medical Case Reports 2024-03, Vol.2024 (3), p.omae014
Main Authors: Aka, Yeliz, Ozdemir, Hulya, Torun, Nese, Bolat, Filiz Aka, Kutuk, Ozgur
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Metastatic breast cancer remains to be a major cause of cancer-related deaths in women. Exploring the molecular mechanisms to identify targetable alterations in progressing breast cancer and developing functional tools to predict therapy response in these patients are needed. In this report, we present a case of breast cancer patient who progressed following surgery and adjuvant endocrine therapy. Radiological and pathological analyses revealed metastasis to liver and brain. Paired liquid biopsies demonstrated acquired ERBB2 mutations in addition to TP53 and PIK3CA mutations, which were also present before progression. BH3 profiling test demonstrated decreased mitochondrial cell death priming in CTCs of the patient after progression. In conclusion, novel personalized treatment strategies are needed to monitor metastatic breast cancer patients for better clinical benefit.
ISSN:2053-8855
2053-8855
DOI:10.1093/omcr/omae014